MAIANYSEPharmaceutical PreparationsFiscal year ends December 31
MAIA Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$1.07−0.03 (-2.73%)
Close on Oct 19, 2026
- Market cap
- $65.05M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.21 (−16.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $65.05M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.15
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$26.85M
- EPS, diluted
- -$0.64
- Book value per share
- $0.34
- Diluted shares
- 61M
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$28.95M
Net income
-$26.85M
EPS, diluted
-$0.64
Reported periodTrailing twelve months